URB597 is a relatively selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 of 4.6 and 0.5 nM in brain membranes and intact neurons, respectively. FAAH is the primary degradatory enzyme for the endocannabinoid anandamide and, as such, inhibition of FAAH leads to an accumulation of anandamide in the CNS and periphery where it activates cannabinoid receptors. URB597 ?produced measurable antidepressant and analgesic effects by increasing endocannabinoids. URB597 ?shows both anti-nociceptive and anxiolytic effects in vivo but not evokes other symptoms associated with cannabinoid-like compounds. Hence, URB597 may provide a new strategy for the treatment of pain and anxiety.
||Adult male Wistar rats (250–300 g) and C57/BL6 or FAAH-/- mice
||sterile 0.9% sodium chloride solution
||Inject subcutaneously in a single dose 2 hours or 16 hours before killing
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
|Body Surface Area (m2)
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by
||Animal B Km
|Animal A Km
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
||DMSO 60 mg/mL